Whalesbook
Dividend ka promise, Share bhaga?
Dekho, Emcure Pharma mein sabse badi baat yeh hai ki 5 May, 2026 ko Board of Directors ki meeting hone wali hai. Is meeting mein Q4FY26 ke audited results aur poore FY26 ke numbers approve honge. Sabse important, yeh log FY26 ke liye final dividend dene par bhi विचार (think) karenge. Isi ummeed mein aaj share price bhag raha hai.
Valuation ka tension toh hai!
Lekin jab baat valuation ki aati hai toh Emcure ka P/E ratio thoda zyada lag raha hai. Iska TTM (Trailing Twelve Months) P/E ratio hai lagbhag 34.67x. Ab compare karo, Dr. Reddy's ka toh sirf 17.2x hai, Zydus Lifesciences ka 19.0x, aur Cipla ka 23.4x. Haan, Sun Pharma (36.6x) ke aas paas hai, aur industry average bhi around 32.9x se 34.7x ke beech mein hai. Matlab, thoda premium toh hai hi.
FIIs ki holding mein changes
Aur ek cheez jo dhyan dene wali hai, woh hai FIIs (Foreign Institutional Investors) ki holding. March 2026 tak FIIs ke paas company ka 3.35% stake tha, jo pehle 3.59% tha. Thoda kam hua hai. Promoter ki holding 77.87% par stable hai aur DIIs ke paas 6.10% hai. Yeh sab ho raha hai jabki overall India ka pharma sector kaafi strong dikh raha hai aur growth ki umeed hai.
Growth kam, Dividend ka zor?
Company ka sales growth pichhle 5 saal mein average 9.36% raha hai. Toh ab sawal yeh uthta hai ki kya yeh high valuation maintain ho payega, khaas kar jab competitors zyada grow kar rahe hain ya unka P/E better hai? Company ke paas diverse portfolio aur global presence toh hai, par sirf dividend announcement se valuation justify karna thoda mushkil ho sakta hai, aur FIIs ka thoda exit bhi isi taraf ishara kar raha hai. Analysts ne iska average price target ₹1,795.67 diya hai, jo zyada bada jump nahi dikhata, par P/E premium abhi bhi ek concern hai.
Analysts kya bol rahe hain?
Par analysts mostly bullish hain. Kai log isko 'Strong Buy' bol rahe hain aur average target ₹1,795.67 ke aas paas hai. Unko lagta hai ki performance aur dividend ki ummeed valuation worries ko overshadow kar degi. Company apna domestic business, new products aur international approvals par kaam kar rahi hai. Par agar margins aur operational efficiency sudhri, tabhi yeh valuation sustainable rahegi.